Please wait while your page loads ...

Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results And Provides An Update On Clinical Development Programs

NDA FOR OMAVELOXOLONE FOR PATIENTS WITH FRIEDREICH’S ATAXIA UNDER REVIEW WITH PDUFA
DATE OF FEBRUARY 28, 2023
FDA DOES NOT PLAN TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS THE OMAVELOXOLONE
NDA AND THE LATE CYCLE MEETING HAS BEEN COMPLETED
PROVIDES UPDATE ON COMMERCIAL PREPARATION


PLANO, Texas—November 8, 2022 (BUSINESS WIRE)—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter of 2022 and provided an update on the Company’s business operations and clinical development programs.

Read the Full article here
 


SHARE
 

Scientific News Archives

Tagged in
Scientific News

Beaker

Privacy Policy      Service Terms      Contact      Charity Navigator